If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
== History == Paniz-Mondolfi was born in Caracas, Venezuela in 1976. His mother is a pediatrician and his father an architect. His grandfather, Edgardo Mondolfi Otero, a biologist and zoologist. Two of his uncles were physicians with special ambitions in the field of sciences and research. His childhood was shared between Caracas and Kenya. Paniz-Mondolfi has a master's degree in parasitology and tropical diseases; he did international fellowships in microbiology, molecular genetics, and skin disease. He also did a second medical residency in the United States in pathology. He isolated and described a new species of parasite that had infected a NY resident, and a new mycobacterium that sickened two people in Connecticut. He earned an MD and PhD and studied under Jacinto Convit the leprosy researcher. He was a pathologist at the IDB Biomedical Research Institute in Barquisimeto, Venezuela until 2019 when he fled to the United States. He is the founder of the Venezuelan Science Incubator, an independent health research organization. Paniz-Mondolfi is assistant professor of pathology, molecular and cell-based medicine at the Mount Sinai Icahn School of Medicine. He is also affiliated with the Yale Cancer Center. In 2020 he focused his research on the COVID-19 pandemic and the effects the virus had on minority children. His research findings have been published in several medical journals including: the European Society of Clinical Microbiology and Infectious Diseases, The American Association for the Advancement of Science, and The Lancet.
A, B, C, D, E, F, G, I, J, K, L, P, Q1, R, S, T, U, V, Z1, Z2 Qi, Jianzhao; Wu, Jing; Kang, Shijie; Gao, Jingming; Hirokazu, Kawagishi; Liu, Hongwei; Liu, Chengwei (August 2024). "The chemical structures, biosynthesis, and biological activities of secondary metabolites from the culinary-medicinal mushrooms of the genus Hericium: a review". Chinese Journal of Natural Medicines. 22 (8): 676–698. doi:10.1016/S1875-5364(24)60590-X. ISSN 1875-5364. Retrieved 2026-01-30.
Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed. TDM aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations. It can be based on an a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) or biological surrogate or end-point markers of effect (pharmacodynamic monitoring). There are numerous variables that influence the interpretation of drug concentration data: time, route and dose of drug given, time of blood sampling, handling and storage conditions, precision and accuracy of the analytical method, validity of pharmacokinetic models and assumptions, co-medications and, last but not least, clinical status of the patient (i.e. disease, renal/hepatic status, biologic tolerance to drug therapy, etc.). Many different professionals (physicians, clinical pharmacists, nurses, medical laboratory scientists, etc.) are involved with the various elements of drug concentration monitoring, which is a truly multidisciplinary process.
Umami ( from Japanese: うま味, pronounced [ɯmami]), or savoriness, is one of the five basic tastes. It is characteristic of broths and cooked meats. People taste umami through taste receptors that typically respond to glutamates and nucleotides, which are widely present in meat broths and fermented products. Glutamates are commonly added to some foods in the form of monosodium glutamate (MSG), and nucleotides are commonly added in the form of disodium guanylate, inosine monophosphate (IMP) or guanosine monophosphate (GMP). Since umami has its own receptors rather than arising out of a combination of the traditionally recognized taste receptors, scientists now consider umami to be a distinct taste. Food, beverages, or condiments that have a strong umami flavor include meats, shellfish, fish (including fish sauce and preserved fish such as Maldives fish, katsuobushi, sardines, and anchovies), dashi, tomatoes, mushrooms, hydrolyzed vegetable protein, meat extract (Bouillon cubes), yeast extract (beer, Marmite, Vegemite), kimchi, cheeses (Parmesan, Asiago cheese, or blue cheese), as well as sauces such as A1 sauce, Worcestershire sauce, and soy sauce. In 1908, Kikunae Ikeda of the University of Tokyo scientifically identified umami as a distinct taste attributed to glutamic acid. As a result, in 1909, Ikeda and Saburōsuke Suzuki founded Ajinomoto Co., Inc.
Alice in Chains – production Dave Jerden – production (except on "Would?"), mixing Rick Parashar – production on "Would?" Bryan Carlstrom – engineering Annette Cisneros – engineering, mixing Ulrich Wild – engineering Steve Hall – mastering Eddy Schreyer – mastering Mary Maurer – art direction, visual effects Doug Erb – cover design David Coleman – logo Rocky Schenck – photography
Sources: en.wikipedia.org
In biochemistry and pharmacology, receptors are proteins that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to a receptor and produce physiological responses, such as a change in the electrical activity of a cell. For example, GABA, an inhibitory neurotransmitter, inhibits electrical activity of neurons by binding to GABAA receptors. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway. Receptor proteins can be classified by their location. Cell surface receptors, also known as transmembrane receptors, include ligand-gated ion channels, G protein-coupled receptors, and enzyme-linked hormone receptors. Intracellular receptors are those found inside the cell, and include cytoplasmic receptors and nuclear receptors. A molecule that binds to a receptor is called a ligand and can be a protein, peptide (short protein), or another small molecule, such as a neurotransmitter, hormone, pharmaceutical drug, toxin, calcium ion or parts of the outside of a virus or microbe. An endogenously produced substance that binds to a particular receptor is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine, but it can also be activated by nicotine and blocked by curare.
The Lund/LBNL Nuclear Data Search – Contains tabulated information on radioactive decay types and energies. Nomenclature of nuclear chemistry Archived 12 February 2015 at the Wayback Machine Specific activity and related topics. The Live Chart of Nuclides – IAEA Interactive Chart of Nuclides Archived 10 October 2018 at the Wayback Machine Health Physics Society Public Education Website Beach, Chandler B., ed. (1914). "Becquerel Rays" . The New Student's Reference Work . Chicago: F. E. Compton and Co. Annotated bibliography for radioactivity from the Alsos Digital Library for Nuclear Issues Archived 7 October 2010 at the Wayback Machine "Henri Becquerel: The Discovery of Radioactivity", Becquerel's 1896 articles online and analyzed on BibNum [click 'à télécharger' for English version]. "Radioactive change", Rutherford & Soddy article (1903), online and analyzed on Bibnum [click 'à télécharger' for English version]
EOSA Promoting the safe use of Ethylene Oxide for Sterilization WebBook page for C2H4O National Institute for Occupational Safety and Health – Ethylene Oxide Topic Page CDC – NIOSH Pocket Guide to Chemical Hazards EOSA memo about Ethylene Oxide (EtO) facts Archived 15 October 2017 at the Wayback Machine
=== BLOSUM === BLOSUM80: more related proteins BLOSUM62: midrange BLOSUM45: distantly related proteins The BLOSUM62 matrix with the amino acids in the table grouped according to the chemistry of the side chain, as in (a). Each value in the matrix is calculated by dividing the frequency of occurrence of the amino acid pair in the BLOCKS database, clustered at the 62% level, divided by the probability that the same two amino acids might align by chance. The ratio is then converted to a logarithm and expressed as a log odds score, as for PAM. BLOSUM matrices are usually scaled in half-bit units. A score of zero indicates that the frequency with which a given two amino acids were found aligned in the database was as expected by chance, while a positive score indicates that the alignment was found more often than by chance, and negative score indicates that the alignment was found less often than by chance.
Other air forces and units using the Mustang included the Royal Australian Air Force's 77 Squadron, which flew Australian-built Mustangs as part of British Commonwealth Forces Korea. The Mustangs were replaced by Gloster Meteor F8s in 1951. F-51s flew in the Air Force Reserve and ANG throughout the 1950s; the very last Mustang in this role was F-51D-30-NA AF serial no. 44-74936, which was finally withdrawn from the West Virginia Air National Guard's 167th Fighter Interceptor Squadron in January 1957 and retired to what was then called the Air Force Central Museum, although it was briefly reactivated to fly at the 50th anniversary of the Air Force Aerial Firepower Demonstration at the Air Proving Ground, Eglin AFB, Florida, on 6 May 1957. This aircraft, painted as P-51D-15-NA serial no. 44-15174, is on display at the National Museum of the United States Air Force, Wright-Patterson AFB, in Dayton, Ohio.
Sources: en.wikipedia.org
Alessio Ciulli (born 22 July 1977) is an Italian British biochemist. Currently, he is the Professor of Chemical & Structural Biology at the School of Life Sciences, University of Dundee, where he founded and directs Dundee' new Centre for Targeted Protein Degradation (CeTPD). He is also the scientific co-founder and advisor of Amphista Therapeutics.
It is often found growing amid normally colored death caps. It has been described, in 2004, as a distinct variety and includes what was termed A. verna var. tarda. The true A. verna fruits in spring and turns yellow with KOH solution, whereas A. phalloides never does.
== Research == Moxidectin is being evaluated as a treatment for scabies. It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.
Enzymes incur catalysis by binding more strongly to transition states than substrates and products. At the catalytic binding site, several different interactions may act upon the substrate. These range from electric catalysis, acid and base catalysis, covalent catalysis, and metal ion catalysis. These interactions decrease the activation energy of a chemical reaction by providing favorable interactions to stabilize the high energy molecule. Enzyme binding allows for closer proximity and exclusion of substances irrelevant to the reaction. Side reactions are also discouraged by this specific binding. Types of enzymes that can perform these actions include oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. For instance, the transferase hexokinase catalyzes the phosphorylation of glucose to make glucose-6-phosphate. Active site residues of hexokinase allow for stabilization of the glucose molecule in the active site and spur the onset of an alternative pathway of favorable interactions, decreasing the activation energy.
Counter-Strike Online is a free-to-play spin-off available in much of eastern Asia. It was developed by Nexon, with oversight from Valve. It uses a micropayment model that is managed by a custom version of the Steam back-end. Announced in 2012 and aimed at the Asian gaming market, a sequel titled Counter-Strike Online 2 was developed by Nexon on the Source game engine and released in 2013.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.